86 related articles for article (PubMed ID: 26093304)
1. Simple synthesis of biocompatible biotinylated porous hexagonal ZnO nanodisc for targeted doxorubicin delivery against breast cancer cell: In vitro and in vivo cytotoxic potential.
Patra P; Mitra S; Das Gupta A; Pradhan S; Bhattacharya S; Ahir M; Mukherjee S; Sarkar S; Roy S; Chattopadhyay S; Adhikary A; Goswami A; Chattopadhyay D
Colloids Surf B Biointerfaces; 2015 Sep; 133():88-98. PubMed ID: 26093304
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
3. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Doxorubicin loaded magnetic chitosan nanoparticles for pH responsive targeted drug delivery.
Unsoy G; Khodadust R; Yalcin S; Mutlu P; Gunduz U
Eur J Pharm Sci; 2014 Oct; 62():243-50. PubMed ID: 24931189
[TBL] [Abstract][Full Text] [Related]
5. Biotin anchored nanostructured lipid carriers for targeted delivery of doxorubicin in management of mammary gland carcinoma through regulation of apoptotic modulator.
Tripathi CB; Parashar P; Arya M; Singh M; Kanoujia J; Kaithwas G; Saraf SA
J Liposome Res; 2020 Mar; 30(1):21-36. PubMed ID: 30741049
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer.
Dong D; Gao W; Liu Y; Qi XR
Cancer Lett; 2015 Apr; 359(2):178-86. PubMed ID: 25592040
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells.
Ke XY; Lin Ng VW; Gao SJ; Tong YW; Hedrick JL; Yang YY
Biomaterials; 2014 Jan; 35(3):1096-108. PubMed ID: 24183698
[TBL] [Abstract][Full Text] [Related]
9. YVO4:Eu3+ functionalized porous silica submicrospheres as delivery carriers of doxorubicin.
Cheng Z; Ma P; Hou Z; Wang W; Dai Y; Zhai X; Lin J
Dalton Trans; 2012 Feb; 41(5):1481-9. PubMed ID: 22124278
[TBL] [Abstract][Full Text] [Related]
10. In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery.
Zou A; Chen Y; Huo M; Wang J; Zhang Y; Zhou J; Zhang Q
J Pharm Sci; 2013 Jan; 102(1):126-35. PubMed ID: 23073894
[TBL] [Abstract][Full Text] [Related]
11. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
[TBL] [Abstract][Full Text] [Related]
13. One platform comparison of estrone and folic acid anchored surface engineered MWCNTs for doxorubicin delivery.
Mehra NK; Jain NK
Mol Pharm; 2015 Feb; 12(2):630-43. PubMed ID: 25517904
[TBL] [Abstract][Full Text] [Related]
14. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
15. Targeted photo-chemo therapy of malignancy on the chest wall while cardiopulmonary avoidance based on Fe3O4@ZnO nanocomposites.
Zhang H; Guo L; Ding S; Xiong J; Chen B
Oncotarget; 2016 Jun; 7(24):36602-36613. PubMed ID: 27153557
[TBL] [Abstract][Full Text] [Related]
16. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
17. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
19. Development of poly (I:C) modified doxorubicin loaded magnetic dendrimer nanoparticles for targeted combination therapy.
Khodadust R; Unsoy G; Gunduz U
Biomed Pharmacother; 2014 Oct; 68(8):979-87. PubMed ID: 25458787
[TBL] [Abstract][Full Text] [Related]
20. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
